IMMP News and Press, Immutep Limited From 05/02/23

Media Release Webinar to take place on Tuesday, May 9, 2023, at 11:30 AM ET SYDNEY, AUSTRALIA, May 02, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and auto...

Media Release Investigator-initiated study jointly funded with Merck KGaA, Darmstadt, Germany, will evaluate dual immuno-oncology (IO) combination of eftilagimod alpha and BAVENCIO® in metastatic urothelial cancer Trial builds on strategy to cost-efficiently increase target indic...

Media Release Final results from Part C of the Phase II TACTI-002 trial in 2nd line head and neck squamous cell carcinoma patients to be presented SYDNEY, AUSTRALIA, April 26, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep...

Media Release SYDNEY, AUSTRALIA, April 26, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune diseases, today announces that Florian D. Vogl, M.D., Ph.D., MSc, has...

Media Release Soft tissue sarcoma, an orphan disease, represents a high unmet medical need with a poor prognosis First time efti will be studied in neoadjuvant, non-metastatic cancer setting Novel triple combination of efti with radiotherapy and anti-PD-1 therapy has potential to ...

2023-04-03 08:18:23 ET Indonesia Energy Corporation  ( NYSE: INDO ) +40% . New Concept Energy ( GBR ) +32% . U.S. Energy  ( USEG ) +29% . Guardforce AI  ( GFAI ) +29% . Barnwell Industries ( BRN ) +22% . Housto...

Media Release Efti plus pembrolizumab achieved mOS of 9.9 months and a 39% OS rate at 21 months, which compare favourably to typical 6-9 months mOS and a 10-15% OS rate for standard-of-care chemotherapy 83% of patients studied for Tumour Growth Kinetics showed deceleration of tumour g...

Media Release Expanding INSIGHT-003 trial evaluating efti with standard-of-care combination of anti-PD-1 therapy and chemotherapy to 50 patients Expansion based on safety and strong initial efficacy results Data updates expected throughout CY2023 and cost-efficient approach throug...

Media Release 2 nd line NSCLC patients refractory to anti-PD-(L)1 treatment have few therapeutic options, and the addition of efti to pembrolizumab may help these patients by reverting anti-PD-(L)1 therapy resistance 83% of patients that were studied for Tumor Growth Kinetics show...

2023-03-14 09:16:22 ET Immutep ( NASDAQ: IMMP ) said it started a phase 2/3 trial of eftilagimod alpha (efti) in combination with paclitaxel to treat metastatic HER2-neg/low breast cancer (MBC). The company has received regulatory approval in the U.S. and greenlight from t...